Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Houston, TX
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Houston, TX
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Mesquite, TX
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Mesquite, TX
Click here to add this to my saved trials
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Salt Lake City, UT
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Caba,
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Paradise Valley, AZ
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Paradise Valley, AZ
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Peoria, AZ
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Peoria, AZ
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Upland, CA
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Upland, CA
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Tamarac, FL
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Tamarac, FL
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigational Site
mi
from
Tampa, FL
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigational Site
mi
from
Tampa, FL
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Canton, GA
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Canton, GA
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Bowling Green, KY
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Bowling Green, KY
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Eagan, MN
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Eagan, MN
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Asheville, NC
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Asheville, NC
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Charlotte, NC
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Greenville, SC
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Jackson, TN
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Jackson, TN
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Nashville, TN
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Houston, TX
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Houston, TX
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Mesquite, TX
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Mesquite, TX
Click here to add this to my saved trials
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  3/8/2016
Novartis Investigative Site
mi
from
Caba,
Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.
A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 3/8/2016
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Birmingham, AL
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Huntsville, AL
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Peoria, AZ
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Riverside, CA
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Upland, CA
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Bridgeport, CT
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Newark, DE
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Ocala, FL
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Port Orange, FL
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Port Orange, FL
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Vero Beach, FL
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Coeur D'Alene, ID
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Frederick, MD
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Frederick, MD
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Lansing, MI
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Freehold, NJ
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Charlotte, NC
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Columbus, OH
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Tulsa, OK
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Lake Oswego, OR
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Columbia, SC
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Myrtle Beach, SC
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Nashville, TN
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
Dallas, TX
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
Clinical Research Facility
mi
from
San Antonio, TX
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated:  3/10/2016
mi
from
Winnipeg,
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 3/10/2016
mi
from
Winnipeg,
Click here to add this to my saved trials